Clinical trial · Interventional
PRECISE: Pancreatic Cancer and Exercise
PRECISE: PancREatic Cancer and Individualised Supervised Exercise: a Feasibility Study
NCT04305067CI-TRIAL-00074063completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to establish the feasibility of delivering a prescribed, individualised supervised aerobic and resistance exercise programme during adjuvant therapy, to improve survival and reduce symptom burden in pancreatic cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Adenocarcinoma | Pancreatic Adenocarcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Exercise | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Supervised aerobic and resistance exercise
- description
- 16 weeks of supervised, moderate intensity, aerobic and resistance exercise. Aerobic exercise will be completed supervised, 2 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous aerobic exercise. Resistance exercises will involve whole body activities and commence with 1 set of each exercise (6-12 repetitions) and progress to 3 sets. The resistance exercises will gradually progress in difficulty throughout the program and will utilise daily undulating periodisation
- interventionNames
- Other: Exercise
Primary outcomes (4)
- measure
- Feasibility - recruitment: number of participants that agree to participate or are excluded
- timeFrame
- At baseline
- description
- The number of participants that agree to participate or are excluded
- measure
- Feasibility - attrition: number of participants that withdraw from the study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * age ≥ 18 years * histologically proven pancreatic ductal adenocarcinoma * complete macroscopic resection (R0 or R1 resection) * patients recovering from surgery in time for chemotherapy to be delivered with adjuvant intent * prior malignancy active within the previous 3 years other than locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * deemed medically fit by treating team to participate in exercise programme * able to provide informed consent. Exclusion Criteria: * Macroscopically remaining tumour (R2 resection or tumour node metastasis (TNM) stage IV disease) * Pre-existing cardiac conditions; Congestive heart failure or recent serious cardiovascular event * Chest pain while undertaking physical activity * Any related co-morbidities (diabetes; unstable angina; degenerative neuromuscular disease; mental health disorders; substance abuse)
References
Publications (1)
- DERIVEDBrown M, O'Connor D, Turkington R, Eatock M, Vince R, Hulme C, Bowdery R, Robinson R, Wadsley J, Maraveyas A, Prue G. Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series. BMC Sports Sci Med Rehabil. 2023 Sep 21;15(1):116. doi: 10.1186/s13102-023-00722-3. PMID 37735664